TCM
ELVN icon

TD Capital Management’s Enliven Therapeutics ELVN Stock Holding History

TD Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16
Closed -$315 – 728
2025
Q1 		$315 Buy
+16
New +$344 ﹤0.01% 631

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TD Capital Management's ELVN Position: Q2 2025 in Review

TD Capital Management sold out of Enliven Therapeutics (ELVN) in Q2 2025, closing a stake of 16 shares — an estimated $315 sold.

TD Capital Management first reported a position in ELVN in Q1 2025 and held it in 1 quarter. The position peaked at $315 in Q1 2025. 124 funds tracked by Wall St. Rank hold ELVN as of Q2 2025.

  • TD Capital Management reported no remaining Enliven Therapeutics position as of Q2 2025 after selling out during the quarter.
  • TD Capital Management sold 16 Enliven Therapeutics shares in Q2 2025, an estimated $315.
  • TD Capital Management first reported a position in Enliven Therapeutics in Q1 2025 and held it in 1 quarter.
  • TD Capital Management's Enliven Therapeutics position peaked at $315 in Q1 2025.
  • 124 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2025.

Based on TD Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.